Evidence map›Paper›PMID 40301570›Full record

Trial reportScientific reports2025

A noninferiority cluster randomised evaluation of a broflanilide indoor residual spraying insecticide, VECTRON T500, for malaria vector control in Tanzania.

Njelembo J Mbewe, Patrick K Tungu, Louisa A Messenger, John Bradley, Peter E Mangesho, Boniface Shirima, Oliver Moshi, Magreth F Shayo, Mohammed Seif, Natalie M Portwood and 12 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05150808 (WHO Phase III Evaluation of Vectron T500), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05150808 phase3unknown statusnot on this map

WHO Phase III Evaluation of Vectron T500 (Broflanilide 50WP) for IRS in Tanzania

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2020 to 2022Enrolled12,500ConditionsMalaria,FalciparumArmsIRS insecticide: Vectron T500
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Njelembo J MbeweDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK. njelembombewe@yahoo.com.
Patrick K TunguDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.
Louisa A MessengerDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.
John BradleyDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.
Peter E MangeshoPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Boniface ShirimaDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Oliver MoshiDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Magreth F ShayoDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Mohammed SeifPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Natalie M PortwoodDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.
Janneke SnetselaarInnovative Vector Control Consortium, Liverpool, UK.
Salum AziziDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Frank MagogoPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Peter MabengaPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Wema SudiPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
George MlayPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Matthew J KirbyDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.
Franklin W MoshaDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
William KisinzaPan-African Malaria Vector Research Consortium PAMVERC, Muheza & Moshi, Tanzania.
Johnson MatowoDepartment of Parasitology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Graham SmallInnovative Vector Control Consortium, Liverpool, UK.
Mark W RowlandDepartment of Disease Control, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK.

Funding

Gates Foundation INV-007509
6 · The paper itself

Abstract

Effective malaria vector control is being undermined by the rapid spread of insecticide resistance. VECTRON T500, a new indoor residual spraying (IRS) product containing the active ingredient broflanilide as a 50% wettable powder (WP), was previously shown to be efficacious in experimental hut trials. A two-arm non-inferiority cluster randomized controlled community trial was conducted in Muheza District, Tanga Region, Tanzania. VECTRON T500 was compared to the IRS product Fludora Fusion (clothianidin 50% + deltamethrin 6.25% WP-SB). Sixteen village clusters were pair-matched on baseline vector densities and allocated to reference and intervention arms. Monthly CDC light trapping sampled mosquitoes to estimate vector density, indoor biting, sporozoite and entomological inoculation rate (EIR). The non-inferiority margin of mosquito density was defined as a density ratio of 1.5. Susceptibility to IRS active ingredients was assessed in one of the local vectors, Anopheles gambiae sensu lato (s.l.), using WHO/CDC bottle bioassays. The residual efficacy of both IRS products was monitored for 12 months using susceptible and pyrethroid resistant An. gambiae sensu stricto (s.s.) mosquitoes. This study is registered with ClinicalTrials.gov (NCT05150808). A total of 916 and 844 houses were sprayed with Fludora Fusion and VECTRON T500, respectively, with equitable spray coverage. An. gambiae s.l. was resistant to deltamethrin but susceptible to clothianidin and broflanilide. The density ratio adjusted for baseline Anopheline mosquito density was 0.77 (95% CI: 0.45-1.29). The baseline adjusted sporozoite rate and EIR differences between the two trial arms were 0.84% and 15.61%, respectively. The residual efficacy was > 80% mortality for VECTRON T500 and Fludora Fusion, on both mud and concrete walls, 12 months post spraying. VECTRON T500 was non-inferior to Fludora Fusion in terms of its ability to reduce vector density, sporozoite rate and EIR, providing an additional vector control tool with a new mode of action for malaria prevention and insecticide resistance management.

Indexed as

AnophelesFluorobenzenesInsecticidesMalariaMosquito ControlMosquito VectorsAnimalsFemaleHumansInsecticide ResistanceNitrilesPyrethrinsTanzaniadecamethrinFluorobenzenesInsecticidesNitrilesPyrethrins

Identifiers

PMID40301570
PMCPMC12041253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.